CoChat

Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: two randomized crossover non-inferiority studies

Open access

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Introduction: To prevent medical sequelae of severe hypoglycemic emergencies, prompt and reliable rescue intervention is critically important. A ready-to-use, liquid stable glucagon, administered subcutaneously by glucagon autoinjector (GAI), Gvoke HypoPen (glucagon injection; Xeris Pharmaceuticals), was evaluated for rescue treatment of severe hypoglycemia. Research design and methods: Two phase III, randomized, controlled, blinded, non-inferiority crossover studies were conducted in 161 adults with type 1 diabetes to compare 1 mg doses of GAI versus glucagon emergency kit (GEK) for treating insulin-induced severe hypoglycemia. Efficacy was evaluated as either a return of plasma glucose to >70 mg/dL (3.9 mmol/L) or increase ≥20 mg/dL (1.1 mmol/L) from a baseline glucose of <50 mg/dL (2.9 mmol/L), within 30 min of dosing. Results: For successful plasma glucose recovery within 30 min, treatment with GAI was non-inferior to GEK. Treatment with GAI was non-inferior to GEK for a plasma glucose >70 mg/dL (3.9 mmol/L) or neuroglycopenic symptom relief within 30 min. From administration of glucagon, the mean time to achieve plasma glucose >70 mg/dL (3.9 mmol/L) or increase ≥20 mg/dL (1.1 mmol/L) was 13.8±5.6 min for GAI and 10.0±3.6 min for GEK. This mean time does not account for the significantly shorter (p<0.0001) drug preparation and administration time for GAI (27.3±19.7 s) versus GEK (97.2±45.1 s). The incidence of treatment emergent adverse events was comparable in both groups. Conclusions: A ready-to-use GAI was non-inferior to GEK, with a similar tolerability profile. GAI is an effective, safe, and well-tolerated rescue treatment for severe hypoglycemia and is a viable alternative to GEK. Trial registration numbers: NCT02656069 and NCT03439072.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjdrc-2021-002137

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 XSGP-303 – ITT population. (A) Number of participants with an average neuroglycopenic score >1 by nominal time from injection and treatment group; (B) mean neuroglycopenic symptom score and mean plasma glucose (mg/dL) by nominal time from injection and treatment group; and (C) mean hypoglycemia symptom score and mean plasma glucose (mg/dL) by nominal time from injection and treatment group. GAI, glucagon autoinjector; GEK, glucagon emergency kit; ITT, intent-to-treat.
Figure 1 XSGP-303 – ITT population. (A) Number of participants with an average neuroglycopenic score >1 by nominal time from injection and treatment group; (B) mean neuroglycopenic symptom score and mean plasma glucose (mg/dL) by nominal time from injection and treatment group; and (C) mean hypoglycemia symptom score and mean plasma glucose (mg/dL) by nominal time from injection and treatment group. GAI, glucagon autoinjector; GEK, glucagon emergency kit; ITT, intent-to-treat.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 22

Metadata

Authors
Christiansen, M. P., Cummins, M., Prestrelski, S., Close, N. C., Nguyen, A., & Junaidi, K.
Affiliations
  • Diablo Clinical Research (US)
  • Xeris Pharmaceuticals (United States) (US)
  • EmpiriStat Inc, Kitty Hawk, North Carolina, USA
Corresponding author
Junaidi, Khaled
Venue
BMJ Open Diabetes Research & Care
Publisher
BMJ
Published
2021-10
Volume
9
Issue
1
Pages
e002137
ISSN
2052-4897 (ISSN-L)
OpenAlex
W3203034103
Cited by
22
References
21
Citations by year
2026: 1 · 2025: 1 · 2024: 5 · 2023: 6 · 2022: 6
FWCI
3.17
Type
journal article
Language
en
Open access
Locations
  • BMJ Open Diabetes Research & Care (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Xeris Pharmaceuticals, Inc. (N/A)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
Keywords
glucagon, severe hypoglycemia, type 1 diabetes, insulin-induced hypoglycemia, neuroglycopenic symptoms, non-inferiority, treatment-emergent adverse events, drug tolerability
MeSH terms
Blood Glucose, Glucagon, Humans, Hypoglycemia, Insulin, Cross-Over Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: two randomized crossover non-inferiority studies. https://app.cochat.ai/papers/10.1136/bmjdrc-2021-002137
The paper
Christiansen, M. P., Cummins, M., Prestrelski, S., Close, N. C., Nguyen, A., & Junaidi, K. (2021). Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: two randomized crossover non-inferiority studies. BMJ Open Diabetes Research & Care. https://doi.org/10.1136/bmjdrc-2021-002137

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.